PROFILE |
 |
The disease that whispers: ovarian cancer. When diagnosed, it's often too late to treat, and standard treatments can be inadequate. AltaRex is building on research into markers associated with ovarian and other cancers to develop drugs that enhance the body's immunological response to cancer. Its treatment for ovarian cancer, OvaRex, is in late-stage clinical trials; also in trials is BrevaRex, a treatment for myeloma, lung, and prostate cancer. The drugs may have additional applicability to endometrial, breast, and non-small cell lung cancers. The company has a licensing agreement with Biomira, which spun Altarex off in 1995; it also has a deal with Dompe Farmaceutici to market OvaRex in Europe.
COMPETITION |
 |
Centocor, Inc. (dossier)
Corixa Corporation (CRXA)
Genentech, Inc. (DNA)
|
 |
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 0.30
1-Yr. Sales Growth: (45.3)%
Employees: 29
Revenue per employee: $10,344.83
KEY PEOPLE |
 |
Richard E. Bagley
CEO
Edward M. Fitzgerald
CFO
CONTACT INFO |
 |
610 Lincoln St.
Waltham, MA 02451
US
Phone: 781-672-0138
Fax: 781-672-0142
Online: Web Site
|